New findings on optimal duration of trastuzumab therapy for women with HER2+ early breast cancer
Monday, October 1, 2012 - 09:00
in Health & Medicine
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were just released.